These results suggest that DTL-RUVBL1/2-β-catenin complex has a potential role in breast cancer radiation resistance, and also provides a potential therapeutic target for the clinical treatment of breast cancer radiation resistance. The gene discussed is DTL; the disease is breast carcinoma.